Positive Phase 3 results from Moderna and Merck’s intismeran autogene, a personalized mRNA neoantigen vaccine combined with Keytruda, represent the main catalyst for trader sentiment. The INTerpath-001 trial in 1,137 high-risk melanoma patients showed a 42% reduction in recurrence or death risk versus Keytruda alone at two years (82.2% vs. 70% recurrence-free), with durable benefit confirmed in longer follow-up. Companies are now engaging regulators and preparing a U.S. filing, with analysts projecting possible approval and 2027 launch. Key variables include the FDA’s handling of the combination regimen, individualized manufacturing timelines of roughly six weeks, and whether survival data or confirmatory trials accelerate or delay clearance. Other candidates remain earlier-stage.
基于Polymarket数据的AI实验性摘要。这不是交易建议,也不影响该市场的结算方式。 · 更新于1H6H1D7D30DALL
View resolved

警惕外部链接哦。
警惕外部链接哦。
常见问题